NKTR Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Clear Phase III Development PathA clearly defined Phase III program with target start dates, readouts and a BLA timeline materially reduces development execution uncertainty. This allows management to allocate resources, sequence CRO/site work, and plan commercial preparations well ahead, strengthening long-term program credibility and partnerability.
Strong Pro Forma Liquidity And RunwayA >$1B cash position and runway into Q3 2028 provide durable funding to initiate and advance global Phase III programs without immediate dilution. This liquidity supports multi-year trial execution, patient enrollment, and partner negotiations, lowering near-term financing risk and enabling strategic optionality through pivotal stages.
Differentiated Mechanism And Favorable SafetyA distinct Treg‑stimulating MOA and a favorable safety profile versus JAKs constitute a sustainable competitive advantage for chronic indications. Fewer monitoring constraints and improved tolerability can expand prescriber acceptance, support broader label positioning, and sustain long‑term market share if efficacy is confirmed in pivotal trials.
Bears Say
Persistent High Cash BurnConsistent negative operating and free cash flow (~-$204M TTM) means the company will continue to rely on financing or existing reserves to fund development. Even with current cash, sustained burn through Phase III increases dilution risk over time and constrains flexibility for opportunistic investments or faster commercialization.
Large Ongoing Operating And Net LossesDeep negative margins reflect structural unprofitability absent product revenue. Persistent operating losses depress return potential for shareholders, can limit reinvestment capacity, and make future financing terms more dilutive or costly, especially if pivotal trials extend timelines or require additional studies to meet regulators' expectations.
Regulatory And Trial Execution RiskOutstanding regulatory design questions for alopecia areata and the logistical complexity of ~150‑site global Phase IIIs create durable execution risk. Misalignment on endpoints or slow enrollment can delay approvals, increase spend, and potentially require additional trials, materially impacting timelines and commercial prospects.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is CHF2.09B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 2 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on May 07, 2026. The company reported -CHF1.467 earnings per share for the quarter, missing the consensus estimate of -CHF1.275 by -CHF0.192.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -1.59.
How many shares outstanding does Nektar Therapeutics have?
Currently, no data Available
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -CHF1.467 in its last earnings report, missing expectations of -CHF1.275. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in CH:NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF134.98 (― Upside)
CHF134.98 (― Upside)
Blogger Sentiment
Bullish
CH:NKTR Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth CHF34.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
187.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
197.87%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
NKTR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivered strong clinical progress and a clear, accelerated path to Phase III for REZPEG in atopic dermatitis and alopecia areata, supported by robust Phase IIb data (durable and deepening responses, EASI‑100 increases, SALT‑20 gains) and a fortified balance sheet (> $1B pro forma). Key positives include well‑defined Phase III designs, meaningful market opportunity, favorable safety signals versus JAK inhibitors, and additional pipeline and TrialNet collaboration in type 1 diabetes. Main concerns are typical biotech risks: ongoing net losses and increasing R&D spend as Phase III programs start, noncash interest expense, remaining regulatory/endpoint design questions (especially for AA and potential moderate AA expansion), and operational enrollment/execution risk for global trials. On balance, the positives (clinical validation, financing, program advancement) outweigh the near‑term financial and execution risks.View all CH:NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
―Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―